Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data on the long-term effects of SNS-301, a first-in-class cancer immunotherapy, both targeting a novel tumor specific embryonic antigen, human aspartate β-hydroxylase (ASPH), at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia March 29 – April 3, 2019.

READ MORE